The Amended and Restated Technology Commercialisation and License Agreement, signed in 2013 between Silex and GLE, is an exclusive worldwide license for exploitation of the SILEX technology for uranium enrichment. Silex’s potential acquisition of a 51% interest in GLE will not affect the license agreement between Silex and GLE, under which Silex will be entitled to a perpetual royalty of between 7 – 12% on revenues generated by GLE from any future use of the SILEX technology, including the Paducah commercial plant opportunity detailed below. 

Further milestone payments of US$20m will also be payable to Silex in the event the SILEX technology is commercialised by GLE.

A US$15m milestone payment was also received by Silex in July 2013. This was  triggered by the successful completion of the Test Loop Phase 1 Program Milestone: Technology Demonstration and Validation.

 

 

Contact us

Registered Office:
Lucas Heights Science and Technology Centre New Illawarra Road
Lucas Heights NSW 2234
Australia

Postal Address:
PO Box 75
Menai Central NSW 2234
Australia


General Enquiries:
enquiries@silex.com.au

Investor Relations:
investor.relations@silex.com.au
Call: +61 2 9704 8888